OncoMatch/Clinical Trials/NCT06040970
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Is NCT06040970 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Sacituzumab and Cisplatin for ovarian cancer.
Treatment: Sacituzumab · Cisplatin — This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer. The goal of the study is to determine the optimal dose of sacituzumab govitecan for use in combination with cisplatin for treatment of epithelial ovarian and endometrial cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Tumor Agnostic
Performance status
WHO 0–1
Prior therapy
Must have received: platinum-based chemotherapy
platinum-sensitive, defined as progression of disease beyond 6 months from the last dose of platinum-based chemotherapy
Cannot have received: sacituzumab govitecan
Prior therapy with sacituzumab govitecan ... at any time for early stage disease
Cannot have received: irinotecan
Prior therapy with ... irinotecan ... at any time for early stage disease
Cannot have received: Trop-2-directed antibody drug conjugate
Prior therapy with ... Trop-2-directed antibody drug conjugate ... at any time for early stage disease
Cannot have received: topoisomerase I-containing antibody-drug conjugate
Prior therapy with ... any topoisomerase I-containing antibody-drug conjugates at any time for early stage disease
Cannot have received: investigational agent
Any investigational agents or study drugs from a previous clinical study within 28 days or 5 half-lives (whichever is longer) of the first dose of study treatment
Cannot have received: chemotherapy
Any other chemotherapy ... within 14 days of the first dose of study treatment
Cannot have received: immunotherapy
Any other ... immunotherapy ... within 14 days of the first dose of study treatment
Cannot have received: anticancer agent
Any other ... anticancer agents within 14 days of the first dose of study treatment
Cannot have received: radiotherapy (wide field)
Radiotherapy with a wide field of radiation within 4 weeks ... of the first dose of study treatment
Cannot have received: radiotherapy (limited field for palliation)
radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment
Cannot have received: major surgery
Exception: excluding placement of vascular access
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment
Lab requirements
Blood counts
hemoglobin ≥ 8.5 g/dl; absolute neutrophil count ≥ 1500/mm3; platelets ≥ 100,000/μl
Kidney function
creatinine clearance ≥ 50 ml/min per the cockcroft-gault equation
Liver function
total bilirubin ≤ 1.5 uln; ast(sgot)/alt(spgt) ≤ 2.5x uln or ≤ 5 x uln if known liver metastases; serum albumin > 3 g/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify